USANA Health Sciences, Inc. (USNA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Chromadex Corp.

Nature's Sunshine Products, Inc.

USANA Health Sciences, Inc.

ProPhase Labs, Inc.

Upexi, Inc.

Natural Alternatives International, Inc.

LifeVantage Corp.

Revolution Medicines, Inc.

Cidara Therapeutics, Inc.

MIRA Pharmaceuticals, Inc.

Bright Green Corp.

Why is USANA Health Sciences, Inc. ?

The company has declared negative results for the last 7 consecutive quarters

INTEREST(HY) At USD 0.67 MM has Grown at 550.49%
OPERATING CASH FLOW(Y) Lowest at USD 63.01 MM
NET PROFIT(HY) At USD 19.06 MM has Grown at -29.34%

With ROE of 6.57%, it has a attractive valuation with a 1.03 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -45.71%, its profits have fallen by -43.8%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -45.71% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is USANA Health Sciences, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

USANA Health Sciences, Inc.

-38.91%

-1.18

47.62%

S&P 500

14.9%

0.70

20.15%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-4.00%

EBIT Growth (5y)

-22.03%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.30

Sales to Capital Employed (avg)

1.70

Tax Ratio

47.24%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

65.57%

ROCE (avg)

70.81%

ROE (avg)

18.61%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.60

EV to EBIT

3.47

EV to EBITDA

1.95

EV to Capital Employed

0.45

EV to Sales

0.19

PEG Ratio

Dividend Yield

ROCE (Latest)

13.08%

ROE (Latest)

4.67%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

INTEREST COVERAGE RATIO(Q)

Highest at 22,386.18

OPERATING PROFIT(Q)

Highest at USD 27.53 MM

OPERATING PROFIT MARGIN(Q)

Highest at 12.17 %

PRE-TAX PROFIT(Q)

At USD 17.61 MM has Grown at 47.4%

-22What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD 25.74 MM

INTEREST(9M)

At USD 0.43 MM has Grown at 88.21%

ROCE(HY)

Lowest at 1.92%

CASH AND EQV(HY)

Lowest at USD 303.73 MM

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.61 times

NET PROFIT(Q)

Lowest at USD -6.9 MM

Here's what is working for USANA Health Sciences, Inc.

Interest Coverage Ratio

Highest at 22,386.18

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Profit

Highest at USD 27.53 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at 12.17 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

At USD 17.61 MM has Grown at 47.4%

over average net sales of the previous four periods of USD 11.94 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Depreciation

Highest at USD 10.29 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for USANA Health Sciences, Inc.

Net Profit

At USD -6.9 MM has Fallen at -262.54%

over average net sales of the previous four periods of USD 4.25 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest

At USD 0.43 MM has Grown at 88.21%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Cash Flow

Lowest at USD 25.74 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Net Profit

Lowest at USD -6.9 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Cash and Eqv

Lowest at USD 303.73 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio

Lowest at 2.61 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio